New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.

Aptevo Therapeutics Inc. (NASDAQ:APVO) shares plunged about 18% on Tuesday even after the company reported promising interim clinical results for its acute myeloid leukemia (AML) treatment candidate, ...

The clinical-stage biotechnology company announced that mipletamig, combined with venetoclax and azacitidine, delivered an 86% clinical benefit rate in newly diagnosed acute myeloid leukemia patients ...

Selected as a C-Further program with up to $1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial ...

Zemcelpro (R) (dorocubicel), also known as UM171 Cell Therapy, is a novel personalized cryopreserved haematopoietic stem cell transplantation product containing two components, namely UM171-expanded ...

Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred herein as 'Ascentage Pharma,” the 'Company,” 'we,” 'us” or 'our”), a global, commercial stage, integrated ...

Incidence of acute leukemia in pregnancy is extremely low, symptoms overlap with gestation, and delayed diagnosis amplifies the need for coordinated hematology–maternal-fetal management. A 23-patient ...